![[SIGN thistle header]](../../../images/page-header-template.jpg)
Methodology Checklist 4: Case-control Studies
Study identification (Include author, title, year of publication, journal title, pages)
|
|||||||
Guideline topic: |
Key Question No:
|
||||||
Before completing this checklist, consider:
|
|||||||
Reason for rejection: Reason for rejection: 1. Paper not relevant to key question □ 2. Other reason □ (please specify):
|
|||||||
Checklist completed by:
|
|||||||
Section 1: Internal validity |
|||||||
In an well conducted case control study: |
In this study the criterion is:
|
||||||
1.1 |
The study addresses an appropriate and clearly focused question |
Well covered |
Not addressed
|
||||
Selection of subjects |
|||||||
1.2 |
The cases and controls are taken from comparable populations |
Well covered |
Not addressed
|
||||
1.3 |
The same exclusion criteria are used for both cases and controls |
Well covered |
Not addressed
|
||||
1.4 |
What percentage of each group (cases and controls) participated in the study? |
Cases:
|
|||||
1.5 |
Comparison is made between participants and non-participants to establish their similarities or differences |
Well covered |
Not addressed
|
||||
1.6 |
Cases are clearly defined and differentiated from controls |
Well covered |
Not addressed
|
||||
1.7 |
It is clearly established that controls are non-cases |
Well covered |
Not addressed
|
||||
ASSESSMENT |
|||||||
1.8 |
Measures will have been taken to prevent knowledge of primary exposure influencing case ascertainment |
Well covered |
Not addressed
|
||||
1.9 |
Exposure status is measured in a standard, valid and reliable way |
Well covered |
Not addressed
|
||||
CONFOUNDING |
|||||||
1.10 |
The main potential confounders are identified and taken into account in the design and analysis |
Well covered |
Not addressed
|
||||
STATISTICAL ANALYSIS
|
|||||||
1.11 |
Confidence intervals are provided |
|
|||||
Section 2: OVERALL ASSESSMENT OF THE STUDY |
|||||||
2.1 |
How well was the study done to minimise the risk of bias or confounding? |
|
|||||
2.2 |
Taking into account clinical considerations, your evaluation of the methodology used, and the statistical power of the study, are you certain that the overall effect is due to the study intervention? |
|
|||||
2.3 |
Are the results of this study directly applicable to the patient group targeted by this guideline? |
|
|||||
2.4 |
Notes. Summarise the authors conclusions. Add any comments on your own assessment of the study, and the extent to which it answers your question. |
||||||
|
|
||||||
The following section is provided for non-SIGN users of this checklist and is being developed to conform to the standards set by the Guidelines International Network Evidence Tables Working Group. |
|||||||
Section 3: description OF THE STUDY |
|||||||
3.1 |
Do we know who the study was funded by? |
□ Academic Institution □ Healthcare Industry |
|||||
3.2 |
How many centres are patients recruited from? |
|
|||||
3.3 |
From which countries are patients selected? (Select all those involved. Note additional countries after “Other”) |
□ Scotland □ UK □ USA □ Canada |
|||||
3.4 |
What is the social setting (ie type of environment in which they live) of patients in the study? |
□ Urban □ Rural □ Mixed |
|||||
3.5 |
What criteria are used to decide who should be cases? |
|
|||||
3.6 |
What criteria are used to decide who should be controls? |
|
|||||
3.7 |
What exposure or risk factor is investigated in the study? (Include dosage where appropriate) |
|
|||||
3.8 |
How long were patients followed-up for? |
|
|||||
3.9 |
List the key characteristics of the patient population. Note if there are any significant differences between different arms of the trial. |
|
|||||
3.10 |
Record the basic data for each arm of the study. If there are more than four arms, note data for subsequent arms at the bottom of the page. |
||||||
|
Cases: |
Cases: |
|||||
3.11 |
Notes. Summarise the authors conclusions. Add any comments on your own assessment of the study, and the extent to which it answers your question. {Much of this is likely to be contributed by GDG members). |
||||||
|
|
||||||